GRI Bio, Inc.

GRI Healthcare Biotechnology

EPS
+97.5%
Free cash flow
+54.3%

Quarter to June 2026, against a year earlier

1.84 0.29 +18.71%
Market cap
$3.4M
P/E
0.0×
Fwd P/E
−4.2×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.30 14.21 3.25 1.70
Net Debt/EBITDA
6.64 5.52 3.09 1.21
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.80) (2.97) (30.29) (24.71)
Book value per Share
5.70 8.50 61.18 21.29
Free Cash Flow
(1.45) (3.68) (2.97) (2.31)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026